- Home
- COGT vs BBNX Comparison
COGT vs BBNX Comparison
Compare COGT & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- BBNX
- Stock Information
- Founded
- COGT 2014
- BBNX 2015
- Country
- COGT United States
- BBNX United States
- Employees
- COGT 205
- BBNX N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- COGT Health Care
- BBNX Health Care
- Exchange
- COGT Nasdaq
- BBNX Nasdaq
- Market Cap
- COGT 822.0M
- BBNX 841.5M
- IPO Year
- COGT 2018
- BBNX 2025
- Fundamental
- Price
- COGT $7.23
- BBNX $17.89
- Analyst Decision
- COGT Buy
- BBNX Strong Buy
- Analyst Count
- COGT 6
- BBNX 10
- Target Price
- COGT $15.20
- BBNX $25.20
- AVG Volume (30 Days)
- COGT 2.1M
- BBNX 504.1K
- Earning Date
- COGT 08-05-2025
- BBNX 08-06-2025
- Dividend Yield
- COGT N/A
- BBNX N/A
- EPS Growth
- COGT N/A
- BBNX N/A
- EPS
- COGT N/A
- BBNX N/A
- Revenue
- COGT N/A
- BBNX $69,830,000.00
- Revenue This Year
- COGT N/A
- BBNX $32.79
- Revenue Next Year
- COGT N/A
- BBNX $36.59
- P/E Ratio
- COGT N/A
- BBNX N/A
- Revenue Growth
- COGT N/A
- BBNX 38911.17
- 52 Week Low
- COGT $3.72
- BBNX $8.89
- 52 Week High
- COGT $12.61
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- COGT 65.40
- BBNX N/A
- Support Level
- COGT $6.88
- BBNX N/A
- Resistance Level
- COGT $7.83
- BBNX N/A
- Average True Range (ATR)
- COGT 0.56
- BBNX 0.00
- MACD
- COGT 0.09
- BBNX 0.00
- Stochastic Oscillator
- COGT 78.17
- BBNX 0.00
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.